PHK
KYMR icon

Point72 Hong Kong’s Kymera Therapeutics KYMR Stock Holding History

Point72 Hong Kong’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,546
Closed -$504K – 557
2025
Q2 		$504K Buy
+11,546
New +$398K 0.03% 247
2022
Q4 		– Sell
-13,379
Closed -$291K – 931
2022
Q3 		$291K Buy
+13,379
New +$353K 0.01% 946
2022
Q2 		– Sell
-1,263
Closed -$53K – 2188
2022
Q1 		$53K Buy
+1,263
New +$53.3K ﹤0.01% 1322
2021
Q2 		– Sell
-518
Closed -$20K – 2149
2021
Q1 		$20K Buy
+518
New +$31.2K ﹤0.01% 1474

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Point72 Hong Kong's KYMR Position: Q3 2025 in Review

Point72 Hong Kong sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 11,546 shares — an estimated $504K sold.

Point72 Hong Kong first reported a position in KYMR in Q1 2021 and held it in 4 quarters. The position peaked at $504K in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Point72 Hong Kong reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 Hong Kong sold 11,546 Kymera Therapeutics shares in Q3 2025, an estimated $504K.
  • Point72 Hong Kong first reported a position in Kymera Therapeutics in Q1 2021 and held it in 4 quarters.
  • Point72 Hong Kong's Kymera Therapeutics position peaked at $504K in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.